Biocept Reports 2020 Fourth Quarter and Full Year Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Biocept (BIOC) Climbs 25% Following Q4 Results
March 29, 2021 4:15 PM EDTBiocept (NASDAQ: BIOC) Climbs 25% Following Q4 Results
... MoreBiocept (BIOC) Q4 EPS Beats Consensus, Revenues Beat (Correction)
March 29, 2021 4:08 PM EDT(Updated - March 30, 2021 10:36 AM EDT)
(Update corrects EPS and headline)
Biocept (NASDAQ: BIOC) reported Q4 EPS of $0.14, beating the analyst estimate of ($0.27). Revenue for the quarter came in at $18.5 million versus the consensus estimate of $12.32 million.
Im exceptionally proud of the Biocept team for their enthusiasm and dedication in supporting the COVID-19 testing needs of our community while advancing our oncology business for a strong post-pandemic future, said Michael Nall, President and CEO of Biocept. Our COVID-19 testing has provided valuable information to our clients, which has helped contain viral spread. We received... More
